Cytotoxic T Lymphocytes Derived from Patients with Chronic Hepatitis C Virus Infection Kill Bystander Cells via Fas-FasL Interaction

Journal of Virology

Volumn 78, Issue 4, 2004, Pages 2152-2157

  Gremion, Christel ^a   Grabscheid, Benno ^a   Wölk, Benno ^c   Moradpour, Darius ^c   Reichen, Jürg ^a   Pichler, Werner ^a   Cerny, Andreas ^b  

^a UNIVERSITY OF BERN   (Switzerland)

^b REGIONAL HOSPITAL OF LUGANO   (Switzerland)

^c UNIVERSITY OF FREIBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

FAS ANTIGEN; FAS LIGAND; HEPATITIS C ANTIGEN; VIRUS PROTEIN;

ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; APOPTOSIS; ARTICLE; BYSTANDER EFFECT; CELL DAMAGE; CELL KILLING; CELL TYPE; COCULTURE; CONTROLLED STUDY; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; FLOW CYTOMETRY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; LIVER CELL; LIVER INJURY; LYMPHOCYTE COUNT; MIXED LYMPHOCYTE CULTURE; MOLECULAR RECOGNITION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION;

EID: 0842304469     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.78.4.2152-2157.2004     Document Type: Article

References (31)

1. Ando, K., K. Hiroishi, T. Kaneko, T. Moriyama, Y. Muto, N. Kayagaki, H. Yagita, K. Okumura, and M. Imawari. 1997. Perform, Fas/Fas ligand, and TNF-alpha pathways as specific and bystander killing mechanisms of hepatitis C virus-specific human CTL. J. Immunol. 158:5283-5291.
2. Bantel, H., A. Lugering, C. Poremba, N. Lugering, J. Held, W. Domschke, and K. Schulze-Osthoff. 2001. Caspase activation correlates with the degree of inflammatory liver injury in chronic hepatitis C virus infection. Hepatology 34:758-767.
3. Berke, G. 1995. The CTL's kiss of death. Cell 81:9-12.
4. Cerny, A., and F. V. Chisari. 1999. Pathogenesis of chronic hepatitis C: immunological features of hepatic injury and viral persistence. Hepatology 30:595-601.
5. Cerny, A., J. G. McHutchison, C. Pasquinelli, M. E. Brown, M. A. Brothers, B. Grabscheid, P. Fowler, M. Houghton, and F. V. Chisari. 1995. Cytotoxic T lymphocyte response to hepatitis C virus-derived peptides containing the HLA A2.1 binding motif. J. Clin. Investig. 95:521-530.
6. Crispe, I. N., T. Dao, K. Klugewitz, W. Z. Mehal, and D. P. Metz. 2000. The liver as a site of T-cell apoptosis: graveyard, or killing field? Immunol. Rev. 174:47-62.
7. Fukuzawa, K., K. Takahashi, K. Futura, T. Tagaya, T. Ishikawa, K. Wada, Y. Omoto, T. Koji, and S. Kakumu. 2001. Expression of fas/fas ligand (fasL) and its involvement in infiltrating lymphocytes in hepatocellular carcinoma (HCC). J. Gastroenterol. 36:681-688.
8. + cytotoxic T-lymphocyte clones. J. Virol. 73:3623-3629.
9. Galle, P. R., W. J. Hofmann, H. Walczak, H. Schaller, G. Otto, W. Stremmel, P. H. Krammer, and L. Runkel. 1995. Involvement of the CD95 (APO-1/ Fas) receptor and ligand in liver damage. J. Exp. Med. 182:1223-1230.
10. + T cells in peripheral blood and liver using peptide-MHC tetramers. Proc. Natl. Acad. Sci. USA 96:5692-5697.
11. Hiramatsu, N., N. Hayashi, Y. Haruna, A. Kasahara, H. Fusamoto, C. Mori, I. Fuke, H. Okayama, and T. Kamada. 1992. Immunohistochemical detection of hepatitis C virus-infected hepatocytes in chronic liver disease with monoclonal antibodies to core, envelope and NS3 regions of the hepatitis C virus genome. Hepatology 16:306-311.
12. Hiramatsu, N., N. Hayashi, K. Katayama, K. Mochizuki, Y. Kawanishi, A. Kasahara, H. Fusamoto, and T. Kamada. 1994. Immunohistochemical detection of Fas antigen in liver tissue of patients with chronic hepatitis C. Hepatology 19:1354-1359.
13. Kägi, D., P. Seiler, J. Pavlovic, B. Ledermann, K. Burki, R. M. Zinkernagel, and H. Hengartner. 1995. The roles of perforin- and Fas-dependent cytotoxicity in protection against cytopathic and noncytopathic viruses. Eur. J. Immunol. 25:3256-3262.
14. Kägi, D., F. Vignaux, B. Ledermann, K. Burki, V. Depraetere, S. Nagata, H. Hengartner, and P. Golstein. 1994. Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity. Science 265:528-530.
15. Kammer, A. R., S. H. van der Burg, B. Grabscheid, I. P. Hunziker, K. M. Kwappenberg, J. Reichen, C. J. Melief, and A. Cerny. 1999. Molecular mimicry of human cytochrome P450 by hepatitis C virus at the level of cytotoxic T cell recognition. J. Exp. Med. 190:169-176.
16. Lau, G. K., G. L. Davis, S. P. Wu, R. G. Gish, L. A. Balart, and J. Y. Lau. 1996. Hepatic expression of hepatitis C virus RNA in chronic hepatitis C: a study by in situ reverse-transcription polymerase chain reaction. Hepatology 23:1318-1323.
17. Lowin, B., M. Hahne, C. Mattmann, and J. Tschopp. 1994. Cytolytic T-cell cytotoxicity is mediated through perform and Fas lytic pathways. Nature 370:650-652.
18. Moradpour, D., B. Grabscheid, A. R. Kammer, G. Schmidtke, M. Groettrup, H. E. Blum, and A. Cerny. 2001. Expression of hepatitis C virus proteins does not interfere with major histocompatibility complex class I processing and presentation in vitro. Hepatology 33:1282-1287.
19. Pinkoski, M. J., T. Brunner, D. R. Green, and T. Lin. 2000. Fas and Fas ligand in gut and liver. Am. J. Physiol. 278:G354-G366.
20. Rehermann, B., and F. V. Chisari. 2000. Cell mediated immune response to the hepatitis C virus. Curr. Top. Microbiol. Immunol. 242:299-325.
21. +-independent T cell-mediated cytotoxicity. J. Exp. Med. 177:195-200.
22. Schneider, P., N. Holler, J. L. Bodmer, M. Hahne, K. Frei, A. Fontana, and J. Tschopp. 1998. Conversion of membrane-bound Fas(CD95) ligand to its soluble form is associated with downregulation of its proapoptotic activity and loss of liver toxicity. J. Exp. Med. 187:1205-1213.
23. Shiota, G., K. Oyama, N. Noguchi, Y. Takano, S. Kitaoka, and H. Kawasaki. 1998. Clinical significance of serum soluble Fas ligand in patients with acute self-limited and fulminant hepatitis. Res. Commun. Mol. Pathol. Pharmacol. 101:3-12.
24. + cytotoxic T lymphocytes. J. Virol. 72:5948-5954.
25. Staege, M. S., J. Schneider, M. Eulitz, S. Scholz, G. W. Bornkamm, T. Wolfel, and A. B. Reske-Kunz. 2000. Consequences of antigen self-presentation by tumor-specific cytotoxic T cells. Immunobiology 201:332-346.
26. Suda, T., T. Okazaki, Y. Naito, T. Yokota, N. Arai, S. Ozaki, K. Nakao, and S. Nagata. 1995. Expression of the Fas ligand in cells of T cell lineage. J. Immunol. 154:3806-3813.
27. Takahashi, T., M. Tanaka, J. Inazawa, T. Abe, T. Suda, and S. Nagata. 1994. Human Fas ligand: gene structure, chromosomal location and species specificity. Int. Immunol. 6:1567-1574.
28. Valiante, N. M., A. D'Andrea, S. Crotta, F. Lechner, P. Klenerman, S. Nuti, A. Wack, and S. Abrignani. 2000. Life, activation and death of intrahepatic lymphocytes in chronic hepatitis C. Immunol. Rev. 174:77-89.
29. Vignaux, F., E. Vivier, B. Malissen, V. Depraetere, S. Nagata, and P. Golstein. 1995. TCR/CD3 coupling to Fas-based cytotoxicity. J. Exp. Med. 181: 781-786.
30. Wölk, B., D. Sansonno, H. G. Kräusslich, F. Dammacco, C. M. Rice, H. E. Blum, and D. Moradpour. 2000. Subcellular localization, stability, and transcleavage competence of the hepatitis C virus NS3-NS4A complex expressed in tetracycline-regulated cell lines. J. Virol. 74:2293-2304.
31. Zinkernagel, R. M., and P. C. Doherty. 1979. MHC-restricted cytotoxic T cells: studies on the biological role of polymorphic major transplantation antigens determining T-cell restriction-specificity, function, and responsiveness. Adv. Immunol. 27:51-177.